ClinicalTrials.gg
CompletedNCT05382221Updated Nov 12, 2026Results posted

Breathe 2 Project 3: Comprehensive Chronic Care

An interventional study of Comprehensive Chronic Care and Standard Care in Smoking Cessation and Smoking Abstinence, sponsored by University of Wisconsin, Madison. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Treatment

How we know

Updated Nov 12, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
979
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies in Smoking Cessation by University of Wisconsin, Madison — 3 open to participants now, 3 under way, none of them phase 3. Smoking Cessation · University of Wisconsin, Madison.

Enrollment
10th of 32
979 · median 561
Started
2022
with 1 other
No phase
13 of 33
none open now
Registered
24th of 33
by date

Among the 33 studies in Smoking Cessation by University of Wisconsin, Madison, this one is the 10th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2022, is one of 13 with no phase, and was the 24th registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

3 of the 33 studies in Smoking Cessation by University of Wisconsin, Madison are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Smoking Cessation by University of Wisconsin, Madison, or all of them as a file.
02

Study summary

This study will evaluate Comprehensive Chronic Care (CCC), a healthcare treatment approach designed to increase smoking treatment engagement and abstinence among primary care patients who smoke. This research will compare CCC with Standard of Care (SC) on the following outcomes: abstinence at 18 months (primary outcome), treatment reach, and cost-effectiveness. Participation in the study will last 18 months.

Read the detailed description

This project is a 2-arm randomized controlled trial (RCT) designed to evaluate whether Comprehensive Chronic Care (CCC), relative to Standard Care (SC), increases smoking abstinence and treatment use in primary care patients who smoke. The aims are as follows:

  • Primary Aim

    • Aim 1: To determine whether Comprehensive Chronic Care (CCC), relative to Standard Care (SC), significantly improves biochemically confirmed 7-day point-prevalence smoking abstinence at 18 months post-enrollment.
  • Secondary Aims

    • Aim 2: To determine the effects of CCC relative to SC on: cost-effectiveness and 7-day point-prevalence smoking abstinence at 6- and 12-months (biochemically confirmed) post-enrollment.
    • Aim 3: To compare CCC with SC on cessation treatment use over 18 months of treatment access.

Comprehensive Chronic Care (CCC) provides ongoing proactive outreach designed to provide support and information about evidence-based smoking treatment, with access to individually validated treatments that are appropriate for patients who are: 1) unwilling quit but willing to reduce; 2) ready to quit; and 3) recovering from an unsuccessful quit attempt.

Standard Care (SC) involves one offer of cessation treatment per year (8 weeks of nicotine patch plus referral to the tobacco quit line).

03

Conditions studied

  • Smoking Cessation
  • Smoking Abstinence

Browse trials for

Keywords

  • Chronic Care Tobacco Treatment
  • Standard of Care
  • Reduction Treatment
  • Motivation Phase Treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • On smoking registry at a participating clinic OR report current smoking at a clinic visit
  • Smoked cigarettes every day in the past 30 days (with or without other forms of tobacco or nicotine)
  • Able to participate in activities (e.g., reports understanding the nature of the study and consent)
  • Able to speak and read English.

Exclusion criteria

Exclusion Criteria:

  • Activated healthcare power of attorney or cognitive impairment that would preclude .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
979 participants (actual)

Study arms

  • Experimental
    Comprehensive Chronic Care

    ongoing proactive outreach designed to provide support and information about evidence-based smoking treatment, with access to individually validated treatments that are appropriate for patients who are: 1) unwilling quit but willing to reduce; 2) ready to quit; and 3) recovering from an unsuccessful quit attempt

    Other: Comprehensive Chronic Care

  • Active comparator
    Standard Care

    involves one offer of cessation treatment (8 weeks of nicotine patch plus referral to the tobacco quit line), annually

    Other: Standard Care

Interventions

  • OtherComprehensive Chronic Care

    Those randomized to CCC will receive smoking treatment offers via the following routes: 1) Four Outreach Calls from a Health Counselor at 4, 8, 12, and 14 months post-study enrollment; 2) Four texts and/or mailings (depending on healthcare system preferences) over 14 months. These outreach contacts will offer cessation treatment or reduction treatment.

  • OtherStandard Care

    one offer of cessation treatment annually

06

What researchers measure

Primary outcomes

  1. Number of Participants With Biochemically Confirmed Point-prevalence Abstinence at 18 Months

    Group differences in abstinence at 18 months will be evaluated using intent-to-treat principle.

    Time frame: up to 18 months

Secondary outcomes

  1. Number of Participants With 7-day Point-prevalence Abstinence at 6 Months

    At 6 months, participants will be asked whether they have smoked in the past 7 days. Group differences in abstinence at 6 months will be evaluated using intent-to-treat principle.

    Time frame: 6 months

  2. Number of Participants With 7-day Point-prevalence Abstinence at 12 Months

    At 12 months, participants will be asked whether they have smoked in the past 7 days. Group differences in abstinence at 12 months will be evaluated using intent-to-treat principle.

    Time frame: 12 months

  3. Group Differences in Cessation Treatment

    Group differences in cessation treatment entry (i.e., Number of participants who initiated greater than 0 cessation treatment calls vs. number of participants who initiated 0 calls).

    Time frame: Up to 18 months

  4. Total Cost of Intervention

    Incremental resource costs related to the CCC intervention include Health Counselor/staff time, administration, staff training, recruitment, and medication. Methods recommended by the United States Panel on Cost-Effectiveness in Health and Medicine will be utilized. Costs will be measured from a societal perspective using direct observational data of health system resource use. Cost estimates will be converted to a common year.

    Time frame: Up to 18 months

  5. Cost Effectiveness Measured by Incremental Cost-effectiveness Ratio (ICER)

    Cost per additional person who quits smoking, for the CCC vs. SC. The ICER is calculated as the difference in total costs between CCC and SC divided by the difference in 18-month quit rates.

    Time frame: Up to 18 months

07

Results

Posted Nov 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneComprehensive Chronic CareStandard Care
Started589390
Completed514364
Not completed7526
Withdrew: Withdrawal by subject5419
Withdrew: Withdrawn by pi40
Withdrew: Death147
Withdrew: Incarcerated30

Outcome measures

PrimaryNumber of Participants With Biochemically Confirmed Point-prevalence Abstinence at 18 Months

Group differences in abstinence at 18 months will be evaluated using intent-to-treat principle.

Time frame:
up to 18 months
Reported as:
Count of participants · Participants
Number of Participants With Biochemically Confirmed Point-prevalence Abstinence at 18 Months
ParticipantsComprehensive Chronic CareStandard Care
Number of Participants With Biochemically Confirmed Point-prevalence Abstinence at 18 Months4737
SecondaryNumber of Participants With 7-day Point-prevalence Abstinence at 6 Months

At 6 months, participants will be asked whether they have smoked in the past 7 days. Group differences in abstinence at 6 months will be evaluated using intent-to-treat principle.

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Participants With 7-day Point-prevalence Abstinence at 6 Months
ParticipantsComprehensive Chronic CareStandard Care
Smoked in past 7 days490353
Abstinent in past 7 days9937
SecondaryNumber of Participants With 7-day Point-prevalence Abstinence at 12 Months

At 12 months, participants will be asked whether they have smoked in the past 7 days. Group differences in abstinence at 12 months will be evaluated using intent-to-treat principle.

Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants With 7-day Point-prevalence Abstinence at 12 Months
ParticipantsComprehensive Chronic CareStandard Care
Smoked in past 7 days499343
Abstinent in past 7 days9047
SecondaryGroup Differences in Cessation Treatment

Group differences in cessation treatment entry (i.e., Number of participants who initiated greater than 0 cessation treatment calls vs. number of participants who initiated 0 calls).

Time frame:
Up to 18 months
Reported as:
Count of participants · Participants
Group Differences in Cessation Treatment
ParticipantsComprehensive Chronic CareStandard Care
Participated in Greater Than 0 Cessation Treatment Calls353250
Participated in 0 Cessation Treatment Calls236140
Statistical analysis
  • Comprehensive Chronic Care vs Standard Care · Regression, Logistic · p = 0.189 · Odds ratio (or): 0.838 · 95% CI 0.643 to 1.091
SecondaryTotal Cost of Intervention

Incremental resource costs related to the CCC intervention include Health Counselor/staff time, administration, staff training, recruitment, and medication. Methods recommended by the United States Panel on Cost-Effectiveness in Health and Medicine will be utilized. Costs will be measured from a societal perspective using direct observational data of health system resource use. Cost estimates will be converted to a common year.

Time frame:
Up to 18 months

Results for this outcome have not been posted.

SecondaryCost Effectiveness Measured by Incremental Cost-effectiveness Ratio (ICER)

Cost per additional person who quits smoking, for the CCC vs. SC. The ICER is calculated as the difference in total costs between CCC and SC divided by the difference in 18-month quit rates.

Time frame:
Up to 18 months

Results for this outcome have not been posted.

Adverse events

Collected over Adverse event data were collected from Target Quit Date until end of cessation period, up to 12 weeks. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Comprehensive Chronic Care14/589 (2.4%)70/589 (11.9%)213/589 (36.2%)
Standard Care7/390 (1.8%)47/390 (12.1%)16/390 (4.1%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventComprehensive Chronic CareStandard Care
HospitalizationSurgical and medical procedures12/58916/390
HospitalizationInfections and infestations13/5897/390
HospitalizationGastrointestinal disorders8/5893/390
HosptitalizationCardiac disorders7/5893/390
HospitalizationVascular disorders6/5893/390
HospitalizationNervous system disorders5/5893/390
HospitalizationPsychiatric disorders2/5893/390
HospitalizationMusculoskeletal and connective tissue disorders4/5890/390
HospitalizationGeneral disorders4/5890/390
HospitalizationInjury, poisoning and procedural complications3/5892/390
Most frequent other events
Most frequent other events
EventComprehensive Chronic CareStandard Care
InsomniaPsychiatric disorders46/5893/390
NauseaGastrointestinal disorders41/5892/390
HeadacheNervous system disorders29/5892/390
IndigestionGastrointestinal disorders28/5890/390
Itch or hivesSkin and subcutaneous tissue disorders24/5894/390
Vivid dreamsPsychiatric disorders23/5893/390
Sore throatGeneral disorders22/5892/390

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Comprehensive Chronic CareStandard CareTotal
Mean53.233 ± 13.026154.023 ± 13.130253.547 ± 13.0667
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Comprehensive Chronic CareStandard CareTotal
Female332219551
Male255171426
Other202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Comprehensive Chronic CareStandard CareTotal
American Indian or Alaska Native437
Asian235
Native Hawaiian or Other Pacific Islander112
Black or African American6861129
White473290763
More than one race191635
Unknown or Not Reported221638
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Comprehensive Chronic CareStandard CareTotal
Hispanic or Latino321345
Not Hispanic or Latino557375932
Unknown or Not Reported022
Self-report Smoking in last 7 days at Baseline
Self-report Smoking in last 7 days at Baseline(Participants)Comprehensive Chronic CareStandard CareTotal
Count of participants589390979
08

Study locations

2 sites
  • UW Health
    Madison, Wisconsin 53792, United States
  • Advocate Aurora
    Milwaukee, Wisconsin 53204, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Sep 2025, 37 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's 37 months is above that.

Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2022
First posted
May 19, 2022
StartActual
Aug 8, 2022
Primary completionActual
Sep 25, 2025
CompletionActual
Sep 25, 2025
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of Participants with biochemically confirmed pointWith Biochemically Confirmed Point-prevalence abstinenceAbstinence at 18 monthsMonthsTime frame: up to 18 months
Nov 12, 2026
Documents
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedNumber of Participants withWith 7-day pointPoint-prevalence abstinenceAbstinence at 6 monthsMonthsTime frame: 6 months
  • EditedNumber of Participants withWith 7-day pointPoint-prevalence abstinenceAbstinence at 12 monthsMonthsTime frame: 12 months
  • EditedGroup differencesDifferences in Cessation TreatmentTime frame: Up to 18 months
  • EditedCost Effectiveness measuredMeasured by incremental costIncremental Cost-effectiveness ratioRatio (ICER)Time frame: Up to 18 months
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of Participants with biochemically confirmed pointWith Biochemically Confirmed Point-prevalence abstinenceAbstinence at 18 monthsMonthsTime frame: up to 18 months
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedNumber of Participants withWith 7-day pointPoint-prevalence abstinenceAbstinence at 6 monthsMonthsTime frame: 6 months
    • EditedNumber of Participants withWith 7-day pointPoint-prevalence abstinenceAbstinence at 12 monthsMonthsTime frame: 12 months
    • EditedGroup differencesDifferences in Cessation TreatmentTime frame: Up to 18 months
    • EditedCost Effectiveness measuredMeasured by incremental costIncremental Cost-effectiveness ratioRatio (ICER)Time frame: Up to 18 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05382221
Responsible party
Sponsor
First posted
May 19, 2022
Start date
Aug 8, 2022
Primary completion
Sep 25, 2025
Completion
Sep 25, 2025
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Jessica Cook, PhD
principal investigator · UW Center of Tobacco Research and Intervention

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion